Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 17 of 17 for “"Cisplatin Resistance"”.
-
Investigating the role of microRNAs and extracellular vesicles in cisplatin resistance in ovarian cancer
… of the contributors to this high mortality is resistance to cisplatin chemotherapy. Resistance to cisplatin is multifactorial involving various networks and tiers of regulation and is not completely understood yet. Among the regulatory molecules in the body, microRNAs have a prominent role in …
-
Circumventing Cisplatin Resistance In Ovarian Cancers Through Reactivation of P53 By Non-Cross-Resistant Platinum Analogs
… <p><strong>CIRCUMVENTING CISPLATIN RESISTANCE IN OVARIAN CANCERS THROUGH REACTIVATION OF P53 BY NON-CROSS-RESISTANT PLATINUM ANALOGS</strong></p> <p><strong>Michelle Martinez-Rivera, B.S.</strong></p> <p><strong>Advisory Professor: Zahid H. Siddik, Ph.D.</strong></p> …
-
THE STUDY OF CD24 AS A PREDICTIVE INDICATOR IN CISPLATIN TREATMENT RESPONSE OF HEAD AND NECK CANCER
… fraction of the patient population responds to cisplatin, with a median survival time of less than a year. Currently, there is a lack of clinically employable molecular characterization of the disease beyond HPV status to classify patients who would respond favorably to platinum-based therapy. …
-
Investigating Checkpoint Kinases 1/2 As Novel Therapeutic Targets In Head and Neck Squamous Cell Carcinoma
<p>Cisplatin, despite being the cornerstone chemotherapy for the treatment of head and neck squamous cell carcinoma (HNSCC), provides clinical benefits in just a subset of patients. This together with the lack of biomarkers predicting therapeutic responses, have led to unacceptably high rate of …
-
Synergistic growth inhibition and enhancement of cell death by combination of Melanoma Differentiation Associated gene-7 (MDA-7/IL-24) and cisplatin in ovarian cancer cell lines
… first-line treatments for ovarian cancer are cisplatin, carboplatin and paclitaxel. However, resistance to these platinum-based drugs occurs in the large majority of initially responsive tumors, resulting in fully chemoresistant, fatal disease. Therefore, the resistance to cisplatin therapy …
-
The cytotoxic effect of higher plant extracts on recurrent ovarian cancer cells
… but some cases have become recurrent due to drug resistance. Higher plant extracts are known to have anticancer effects. The aim of this investigation is to test higher plant extracts against platinum-sensitive and platinum-resistant ovarian cancer cells to show if they have a toxic effect and if …
-
Drug Design, Biological Activity, and Metabolic Consequences of Cytotoxic Platinum Compounds: Utilizing Fluorescent Tagging to Understand Drug Action and Metabolism
… based drugs is limited due to acquired drug resistance and a limited range of tumor types that are treatable with the current regime. The development of novel cytotoxic platinum based compounds, both trans- and polynuclear, provides for the promising treatment of clinical platinum drug …
-
Targeting oncogenic microRNAs in malignant germ cell tumours.
… This common seed region is associated with cisplatin resistance in GCT cells and has dose-dependent effects, with higher levels found in GCT subtypes with inferior outcomes. My hypothesis was that targeting these over-expressed microRNAs would confirm their functional significance, identify …
-
A pathways-based approach identifying determinants of drug resistance in oesophageal adenocarcinoma
… at approximately 15%. The development of drug-resistance limits the effectiveness of current chemotherapies, with less than 20% of patients experiencing complete pathological response, so the discovery of underlying resistance mechanisms and novel agents to target these pathways is …
-
ASSESSING PREDICTIVE MODELING APPROACHES FOR OPTIMIZING THERAPY IN ADVANCED LARYNGEAL AND HYPOPHARYNGEAL CANCERS
… for all patients and may contribute to drug resistance in some cases. Identifying a molecular signature of ICT response in both responsive and non-responsive patients could enable prediction of ICT outcomes in patients with advanced disease, providing valuable insights for therapy decisions. …
-
A Study on the Protein Interaction with Different Platinum Compounds
Since the discovery of anti-tumor activity of cisplatin in 1960, significant progress has been made in treating metastatic or advanced cancer with cisplatin and platinum compounds. Platinum compounds covalently bind to DNA and disrupt DNA function. They are also known to bind with amino acids like …
-
Nanoparticle based chemotherapy for pulmonary drug delivery in treating lung cancer
… to be less than 10 years in 95% of cases. Cisplatin treatment is being considered in all stage non-small cell lung cancer patients with overall benefits of only a 1-year survival gain. Cisplatin has a number of major drawback such as toxicities and the acquisition of cisplatin resistance …
-
The proteomic analysis of resistance to anticancer therapy in human breast cancer
Resistance to anticancer therapy represents a major barrier in the successful management of human breast cancer. The identification of novel biomarkers that correlate with treatment response would increase our understanding of the resistance mechanisms and may allow therapy to be tailored on an …
-
Curcumin as a therapeutic agent for the treatment of rheumatoid arthritis and cancer
… carcinoma cells were treated with curcumin and cisplatin, individually and in combination. Curcumin treatment alone was the most effective and downregulated the expression of 11 inflammatory response genes studied, ANGPTL7, CD248, CH25H, COL14A1, CXCL12, HSPA6, IFITM1, IL-7, MMP1, MMP13 and …
-
Metal complexes with biological activity
… leading cause of death in developed countries. Cisplatin is one of the most chemotherapeutic drug. In spite of its great efficacy, it shows several side effects and most patients develop a resistance to cisplatin. To overcome the cisplatin resistance, drugs are often administered in combination …
-
An implantable hydrogel for the delivery of cisplatin and the ex vivo neurotoxic, neuromyopathic and cardiotoxic activity of platinum-based anticancer drugs and macrocyclic drug delivery systems
Cisplatin is currently a leading anticancer drug used in the treatment of various cancers. Its clinical use, however, is limited by its poor bioavailability, its undesirable toxic side effects profile and by the ability of certain tumours to develop cisplatin resistance. A method that may overcome …
-
Toward an epigenetic classification of human testicular germ cell tumors (TGCTs): preliminary assessment of histone H3-K27 trimethylation according to TGCT subtype, aggressiveness, and response to therapy
Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2026-05-01